Our Company
FluoTech Biosciences is a pioneering biotechnology company dedicated to transforming cardiovascular health through innovative nanomaterial solutions.
At A Glance
Our mission is to address critical global health challenges, particularly atherosclerosis, by developing cutting-edge therapeutic platforms that improve patient outcomes and advance scientific research.
Founded in 2024 : Established by a team of experts in nanotechnology, drug delivery, and biomedical engineering.
Proprietary Technology : FTB-728 nanoparticle platform with unparalleled drug-loading capacity (up to 77.5%) and precise targeting capabilities.
Dual-Market Strategy : Generating immediate revenue through research material sales while advancing long-term therapeutic goals.
Strategic Partnerships : Collaborations with leading institutions like City University of Hong Kong, Johns Hopkins Medicine, and NUS.
Funding : Secured support from HKTECH300, Hong Kong’s premier technology startup program.
Our Company
Fast Growing Bio-Tech Company
FluoTech Biosciences is a rapidly expanding biotechnology company dedicated to transforming healthcare through cutting-edge nanomaterial technologies. Founded in April 2024, we have established robust partnerships with leading institutions and secured funding from HKTECH300, Hong Kong’s premier technology startup program.
At FluoTech, we’re revolutionizing cardiovascular treatment with our FTB-728 platform — combining innovation, precision, and sustainability to fight atherosclerosis and empower researchers globally.
mohamed el. hilal
Founder, CEO of Fluotech Biosciences
Therapeutic Areas of Focus
Atherosclerosis
Atherosclerosis is a chronic cardiovascular disease characterized by plaque buildup in arteries, restricting blood flow and increasing the risk of heart attacks and strokes. It remains a leading global cause of mortality, underscoring the urgent need for innovative therapeutic solutions like ATHRICINE
FluoTech Biosciences is focused on developing ATHRICINE, an advanced therapeutic solution for atherosclerosis. Utilizing our proprietary FTB-728 nanoparticle platform, ATHRICINE offers targeted drug delivery to reduce plaque buildup and inflammation, addressing a significant unmet need in cardiovascular disease treatment.
Awards & Recognition
